<p>根據 Allworth Financial LP 最近向 SEC 提交的 13F 表格，該公司在 2023 年第四季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的持股增加了 106.4%。該公司在此期間額外購買了 111,973 股後，持有 217,248 股該生物製藥公司的股票。Allworth Financial LP 在百時美施貴寶的持股在最近一個季度末的價值為 11,718,000 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>2 只值得投資的巴菲特股票——以及 1 只需要拋棄的股票</li>
</ul>
<p>其他一些對沖基金也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在百時美施貴寶的持股增加了 1.4%。先鋒集團目前持有 198,727,768 股該生物製藥公司的股票，價值 10,719,376,000 美元，此前在此期間額外購買了 2,743,759 股。道富銀行（State Street Corp）在第三季度將其在百時美施貴寶的持股增加了 2.0%。道富銀行目前持有 96,595,232 股該生物製藥公司的股票，價值 4,356,445,000 美元，此前在此期間額外購買了 1,855,238 股。Dimensional Fund Advisors LP 在第三季度將其在百時美施貴寶的持股增加了 11.5%。Dimensional Fund Advisors LP 目前持有 18,143,672 股該生物製藥公司的股票，價值 818,105,000 美元，此前在此期間額外購買了 1,873,618 股。Legal &amp; General Group Plc 在第三季度將其在百時美施貴寶的持股增加了 8.4%。Legal &amp; General Group Plc 目前持有 17,075,743 股該生物製藥公司的股票，價值 770,116,000 美元，此前在此期間額外購買了 1,317,199 股。最後，Pzena Investment Management LLC 在第三季度將其在百時美施貴寶的持股增加了 0.4%。Pzena Investment Management LLC 目前持有 14,901,604 股該生物製藥公司的股票，價值 672,062,000 美元，此前在上個季度額外購買了 58,129 股。76.41% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師設定新的價格目標</h2>
<p>BMY 近期成為多份研究報告的主題。Cantor Fitzgerald 將百時美施貴寶的目標價格從 45.00 美元上調至 54.00 美元，並在 4 月 8 日的研究報告中給予該股票 “中性” 評級。摩根士丹利在 2 月 6 日的研究報告中重申了 “減持” 評級，並對百時美施貴寶的股票設定了 40.00 美元的目標價格。滙豐銀行在 3 月 17 日的研究報告中將百時美施貴寶的目標價格從 53.00 美元上調至 60.00 美元，並給予該股票 “持有” 評級。美國銀行在 4 月 9 日的研究報告中將百時美施貴寶的目標價格從 68.00 美元下調至 67.00 美元，並對該股票設定了 “買入” 評級。最後，加拿大皇家銀行在 2 月 24 日的研究報告中開始覆蓋百時美施貴寶。他們給予該股票 “行業表現” 評級，並設定了 60.00 美元的目標價格。八位研究分析師對該股票給予了買入評級，十位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的當前共識評級為 “持有”，平均目標價格為 61.31 美元。</p>
<ul>
<li>為什麼 GRAIL 股票可能成為生物技術領域的下一個重大突破</li>
</ul>
<p><strong>查看我們對百時美施貴寶的最新股票分析</strong></p>
<h2>百時美施貴寶的內部交易</h2>
<p>在其他百時美施貴寶的新聞中，執行副總裁 David V. Elkins 在 4 月 1 日星期三出售了 30,000 股該股票。該股票以平均價格 61.67 美元出售，總交易額為 1,850,100.00 美元。交易後，該執行副總裁在公司持有 159,248 股，價值約為 9,820,824.16 美元。這代表了他們持股的 15.85% 的減少。該出售在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。公司內部人士持有該公司股票的 0.05%。</p>
<h2>百時美施貴寶股票表現</h2>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>BMY 股票在週五開盤價為 56.76 美元。該公司的市值為 1159.1 億美元，市盈率為 15.94，市盈增長比率為 0.16，貝塔值為 0.26。該公司的 50 日移動平均線為 58.74 美元，200 日移動平均線為 55.34 美元。該公司的流動比率為 1.42，速動比率為 1.28，債務與股本比率為 2.10。百時美施貴寶公司的 12 個月低點為 42.52 美元，12 個月高點為 62.89 美元。</p>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 4 月 30 日星期四發佈了季度財報。該生物製藥公司報告每股收益（EPS）為 1.58 美元，超出分析師的共識預期 1.42 美元，超出幅度為 0.16 美元。該公司在本季度的收入為 114.9 億美元，而共識預期為 109.3 億美元。百時美施貴寶的股本回報率為 64.87%，淨利潤率為 15.01%。百時美施貴寶本季度的收入同比增長 2.6%。在去年同期，該公司每股收益為 1.80 美元。百時美施貴寶已將其 2026 財年的指導目標設定為 6.050-6.350 EPS。分析師預計百時美施貴寶公司在當前財年將發佈 6.3 EPS。</p>
<h2>百時美施貴寶宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，該分紅於 5 月 1 日星期五支付。4 月 2 日星期四的登記股東獲得每股 0.63 美元的分紅。除息日期為 4 月 2 日星期四。這代表了每年 2.52 美元的分紅，收益率為 4.4%。百時美施貴寶的分紅支付比率目前為 70.79%。</p>
<h2>百時美施貴寶簡介</h2>
<p>（免費報告）</p>
<p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。公司的核心業務包括在多個治療領域進行處方藥的研究與開發、臨牀開發、生產和商業化。百時美施貴寶專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
<p>百時美施貴寶的市場產品組合和後期管線反映出對癌症和免疫介導疾病的強烈關注。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們認為比百時美施貴寶更好的股票</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先量子公司的第一季度財報對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在百時美施貴寶嗎？</h2>
<p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥 3 倍做多 - Direxion

標普生物技術 3 倍做多 - Direxion

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

<p>Allworth Financial LP 在第四季度將其在百時美施貴寶（NYSE:BMY）的股份增加了 106.4%，目前持有 217,248 股，價值 1170 萬美元。其他機構投資者也增加了他們的持股。分析師設定的目標價格範圍為 40 美元至 68 美元，普遍評級為 “持有”，平均目標價格為 61.31 美元。該股票開盤價為 56.76 美元，市值為 1159.1 億美元</p>

<p>Allworth Financial LP grew its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 106.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 217,248 shares of the biopharmaceutical company's stock after purchasing an additional 111,973 shares during the period. Allworth Financial LP's holdings in Bristol Myers Squibb were worth $11,718,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>根據 Allworth Financial LP 最近向 SEC 提交的 13F 表格，該公司在 2023 年第四季度將其在百時美施貴寶公司（NYSE:BMY - 免費報告）的持股增加了 106.4%。該公司在此期間額外購買了 111,973 股後，持有 217,248 股該生物製藥公司的股票。Allworth Financial LP 在百時美施貴寶的持股在最近一個季度末的價值為 11,718,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>2 Buffett Stocks to Load Up On—And 1 to Ditch</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只值得投資的巴菲特股票——以及 1 只需要拋棄的股票</li>
</ul>
</div><p>A number of other hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company's stock valued at $10,719,376,000 after purchasing an additional 2,743,759 shares during the period. State Street Corp increased its holdings in shares of Bristol Myers Squibb by 2.0% in the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company's stock valued at $4,356,445,000 after purchasing an additional 1,855,238 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Bristol Myers Squibb by 11.5% in the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company's stock valued at $818,105,000 after purchasing an additional 1,873,618 shares during the period. Legal &amp; General Group Plc increased its holdings in shares of Bristol Myers Squibb by 8.4% in the third quarter. Legal &amp; General Group Plc now owns 17,075,743 shares of the biopharmaceutical company's stock valued at $770,116,000 after purchasing an additional 1,317,199 shares during the period. Finally, Pzena Investment Management LLC boosted its stake in shares of Bristol Myers Squibb by 0.4% in the third quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company's stock worth $672,062,000 after buying an additional 58,129 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些對沖基金也調整了對該公司的持股。先鋒集團（Vanguard Group Inc.）在第四季度將其在百時美施貴寶的持股增加了 1.4%。先鋒集團目前持有 198,727,768 股該生物製藥公司的股票，價值 10,719,376,000 美元，此前在此期間額外購買了 2,743,759 股。道富銀行（State Street Corp）在第三季度將其在百時美施貴寶的持股增加了 2.0%。道富銀行目前持有 96,595,232 股該生物製藥公司的股票，價值 4,356,445,000 美元，此前在此期間額外購買了 1,855,238 股。Dimensional Fund Advisors LP 在第三季度將其在百時美施貴寶的持股增加了 11.5%。Dimensional Fund Advisors LP 目前持有 18,143,672 股該生物製藥公司的股票，價值 818,105,000 美元，此前在此期間額外購買了 1,873,618 股。Legal &amp; General Group Plc 在第三季度將其在百時美施貴寶的持股增加了 8.4%。Legal &amp; General Group Plc 目前持有 17,075,743 股該生物製藥公司的股票，價值 770,116,000 美元，此前在此期間額外購買了 1,317,199 股。最後，Pzena Investment Management LLC 在第三季度將其在百時美施貴寶的持股增加了 0.4%。Pzena Investment Management LLC 目前持有 14,901,604 股該生物製藥公司的股票，價值 672,062,000 美元，此前在上個季度額外購買了 58,129 股。76.41% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
</div><p>BMY has been the topic of a number of recent research reports. Cantor Fitzgerald upped their target price on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a &#34;neutral&#34; rating in a research note on Wednesday, April 8th. Morgan Stanley restated an &#34;underweight&#34; rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. HSBC upped their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a &#34;hold&#34; rating in a research note on Tuesday, March 17th. Bank of America lowered their target price on Bristol Myers Squibb from $68.00 to $67.00 and set a &#34;buy&#34; rating on the stock in a research note on Thursday, April 9th. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a &#34;sector perform&#34; rating and a $60.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $61.31.</p>
<div class="lb-trans"><p>BMY 近期成為多份研究報告的主題。Cantor Fitzgerald 將百時美施貴寶的目標價格從 45.00 美元上調至 54.00 美元，並在 4 月 8 日的研究報告中給予該股票 “中性” 評級。摩根士丹利在 2 月 6 日的研究報告中重申了 “減持” 評級，並對百時美施貴寶的股票設定了 40.00 美元的目標價格。滙豐銀行在 3 月 17 日的研究報告中將百時美施貴寶的目標價格從 53.00 美元上調至 60.00 美元，並給予該股票 “持有” 評級。美國銀行在 4 月 9 日的研究報告中將百時美施貴寶的目標價格從 68.00 美元下調至 67.00 美元，並對該股票設定了 “買入” 評級。最後，加拿大皇家銀行在 2 月 24 日的研究報告中開始覆蓋百時美施貴寶。他們給予該股票 “行業表現” 評級，並設定了 60.00 美元的目標價格。八位研究分析師對該股票給予了買入評級，十位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的當前共識評級為 “持有”，平均目標價格為 61.31 美元。</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 GRAIL 股票可能成為生物技術領域的下一個重大突破</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>查看我們對百時美施貴寶的最新股票分析</strong></p>
</div><h2>Insider Transactions at Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>百時美施貴寶的內部交易</h2>
</div><p>In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.05% of the company's stock.</p>
<div class="lb-trans"><p>在其他百時美施貴寶的新聞中，執行副總裁 David V. Elkins 在 4 月 1 日星期三出售了 30,000 股該股票。該股票以平均價格 61.67 美元出售，總交易額為 1,850,100.00 美元。交易後，該執行副總裁在公司持有 159,248 股，價值約為 9,820,824.16 美元。這代表了他們持股的 15.85% 的減少。該出售在向 SEC 提交的文件中披露，可以通過此超鏈接訪問。公司內部人士持有該公司股票的 0.05%。</p>
</div><h2>Bristol Myers Squibb Stock Performance</h2>
<div class="lb-trans"><h2>百時美施貴寶股票表現</h2>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>Shares of BMY stock opened at $56.76 on Friday. The company has a market capitalization of $115.91 billion, a P/E ratio of 15.94, a P/E/G ratio of 0.16 and a beta of 0.26. The business's 50 day moving average is $58.74 and its two-hundred day moving average is $55.34. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.</p>
<div class="lb-trans"><p>BMY 股票在週五開盤價為 56.76 美元。該公司的市值為 1159.1 億美元，市盈率為 15.94，市盈增長比率為 0.16，貝塔值為 0.26。該公司的 50 日移動平均線為 58.74 美元，200 日移動平均線為 55.34 美元。該公司的流動比率為 1.42，速動比率為 1.28，債務與股本比率為 2.10。百時美施貴寶公司的 12 個月低點為 42.52 美元，12 個月高點為 62.89 美元。</p>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts expect that Bristol Myers Squibb Company will post 6.3 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 4 月 30 日星期四發佈了季度財報。該生物製藥公司報告每股收益（EPS）為 1.58 美元，超出分析師的共識預期 1.42 美元，超出幅度為 0.16 美元。該公司在本季度的收入為 114.9 億美元，而共識預期為 109.3 億美元。百時美施貴寶的股本回報率為 64.87%，淨利潤率為 15.01%。百時美施貴寶本季度的收入同比增長 2.6%。在去年同期，該公司每股收益為 1.80 美元。百時美施貴寶已將其 2026 財年的指導目標設定為 6.050-6.350 EPS。分析師預計百時美施貴寶公司在當前財年將發佈 6.3 EPS。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶宣佈分紅</h2>
</div><p>The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.4%. Bristol Myers Squibb's dividend payout ratio is currently 70.79%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，該分紅於 5 月 1 日星期五支付。4 月 2 日星期四的登記股東獲得每股 0.63 美元的分紅。除息日期為 4 月 2 日星期四。這代表了每年 2.52 美元的分紅，收益率為 4.4%。百時美施貴寶的分紅支付比率目前為 70.79%。</p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百時美施貴寶簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.</p>
<div class="lb-trans"><p>百時美施貴寶是一家全球生物製藥公司，總部位於新澤西州普林斯頓，專注於發現、開發和提供針對嚴重疾病的藥物。公司的核心業務包括在多個治療領域進行處方藥的研究與開發、臨牀開發、生產和商業化。百時美施貴寶專注於通過小分子和生物製劑推進腫瘤學、血液學、免疫學、心血管疾病和特殊領域的治療。</p>
</div><p>BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.</p>
<div class="lb-trans"><p>百時美施貴寶的市場產品組合和後期管線反映出對癌症和免疫介導疾病的強烈關注。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>YETI Rallies After Earnings Beat and Raised Outlook</li>
<li>How the 3 Leading Quantum Firms Stack Up After Q1 Earnings</li>
<li>Cisco’s Vertical Rally May Still Be in the Early Innings</li>
<li>Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比百時美施貴寶更好的股票</li>
<li>YETI 在財報超預期和上調前景後反彈</li>
<li>三家領先量子公司的第一季度財報對比</li>
<li>思科的垂直反彈可能仍處於早期階段</li>
<li>亞馬遜與阿里巴巴：現在顯然更具價值的選擇</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Bristol Myers Squibb Company $BMY Shares Acquired by Allworth Financial LP

Market Beat

道富銀行

Legal & General Group Plc

摩根士丹利

匯豐控股有限公司

滙豐

匯豐控股

美國銀行

加拿大皇家銀行

GRAIL

Bristol-Myers Squibb Company

State Street® US Equity Premium Inc ETF

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

HSBC 5xShortSG241213

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Allworth Financial LP 收購了百時美施貴寶公司 $BMY 的股票